AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 281 min read$TLRY

Tilray Brands (TLRY) CFO’s stock payout set on 96.4% goal

Tilray Brands (TLRY) CFO Carl A. Merton exercised 168,452 performance-based restricted stock units, converting them into common shares. The Compensation Committee certified 96.4% achievement of the performance target, resulting in a 92.8% payout. 92,649 shares were withheld at $4.88 per share for tax obligations.

Original reporting
stocktitan.net
Published Aug 28, 2026, 12:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 2:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$TLRY
Neutral
medium confidence
Mentioned
$TLRY
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TLRYNeutralLow
01

Why it matters

The filing provides fresh data on insider ownership and potential dilution, useful for short‑term positioning.

02

Market read

Primary source filing; modest insider activity with limited market impact.

03

What to watch

Potential future performance‑based awards if EBITDA targets continue to be met could increase dilution.

Relevance 4/10Novelty 4/10Timing: August 26 2026 filing date

Background

Tilray Brands (TLRY) disclosed a Form 4 insider transaction by its CFO, detailing RSU exercises and tax withholdings.

Company-level read

Ticker impact

$TLRYNeutralMedium confidence
Context

CFO Carl A. Merton exercised 168,452 performance‑based RSUs on Aug 26 2026, net buying 75,803 shares after tax withholding.

Expected impact

Minor upward pressure due to insider buying, offset by dilution from new shares.

Evidence & confidence

CFO’s large RSU exercise signals confidence but the net buy is small relative to float; dilution may temper any upside.

Market effects

Sector

No broader sector impact; the filing is company‑specific.

Regional

Limited to Tilray’s U.S. listing; no regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The dilution from RSU conversion could outweigh the modest insider buy, suggesting a slight downside risk.

Key entities

  • company
    Tilray Brands, Inc.

    US‑listed cannabis company (ticker TLRY).

  • person
    Carl A. Merton

    Chief Financial Officer of Tilray.

Read at source← All news

Related articles

AUG 24
$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

aol.com3 min
AUG 23
$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

yahoo.com3 min
AUG 21
$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

fool.com3 min
AUG 7
$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

simplywall.st7 min
JUL 30
$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.

yahoo.com6 min